---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061123"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T11:05:00.131004+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tenaya Q3 net loss $29.1M; first patient dosed in TN-201 HCM trial

## Summary
- Q3 net loss $29.1M ($0.39/share); R&D $23.1M, G&A $7.8M; cash $128.1M into H1 2025.
- First patient dosed in MyPeak-1 Phase 1b trial of TN-201 for MYBPC3-associated HCM.
- FDA cleared TN-401 IND for PKP2-ARVC and granted Fast Track designation in Nov 2023.
- Positive Phase 1 data for TN-301 (HDAC6 inhibitor) in HFpEF presented at HFSA 2023.
- EMA granted Orphan Medicinal Product designation for TN-401 in Sep 2023.

## SEC filing metadata
- accession: 0000950170-23-061123
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017023061123/0000950170-23-061123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017023061123/tnya-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061123
- JSON: https://secwatch.observer/filing/0000950170-23-061123.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061123.txt

## Key facts
- Earnings Releases
  Tenaya Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $29.1 million, or $0.39 per share, EPS $0.39 per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: $29.1 million, or $0.39 per share
  - EPS: $0.39 per share
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2023, was $29.1 million, or $0.39 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017023061123/0000950170-23-061123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.